|
|
||||||||||||||||||||
BACKGROUND The Vascular Endothelial Growth Factor Receptor (VEGFR) family has three members: VEGFR-1 (also known as flt-1), VEGFR-2 (KDR/flk-1), and VEGFR-3 (FLT4). In VEGFR-3, the fifth Ig homology domain of the extracellular portion is proteolytically cleaved and the resulting polypeptides remain linked by twodisulfide bonds.1 The ligands binding to VEGFRs belong tothe VEGF family of growth factors, which has five cellular members: VEGF, placenta growth factor (PlGF), VEGF-B, VEGF-C, VEGF-D, and the recently cloned viral VEGF homologue VEGF-E.2 VEGFR-3 is requiredfor cardiovascular development during embryogenesis. In adults,this receptor is expressed in lymphatic endothelial cells. VEGF-C and VEGF-D are VEGFR3 ligands. The binding of VEGF ligands to VEGFRs activates VEGFR3 signaling, which regulates cardiovascular development, angiogenesis, and lymphangiogenesis.3 RECENT PUBLICATIONS Liu, J., Y. Cheng, M. He, and S. Yao. 2014. Vascular endothelial growth factor C enhances cervical cancer cell invasiveness via upregulation of galectin-3 protein. Gynecological Endocrinology 30:461-465. Stewart, J., X. Ma, M. Megison, H. Nabers, W. Cance, E. Kurenova, and E. Beierle. 2015. Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma. Molecular Carcinogenesis, 54:9-23. REFERENCES 1. Otrock, Z.K. et al. : Blood Cells Mol Dis. 38:258, 2007. 2. Taipale, J. et al.: Curr Top Microbiol Immunol. 237:85, 1999. 3. Su, J.L. et al.: Br J Cancer. 96:541, 2007. Products are for research use only. They are not intended for human, animal, or diagnostic applications. 
Параметры
*Optimal working dilutions must be determined by end user. ДокументыПубликации
2015
Stewart, J., X. Ma, M. Megison, H. Nabers, W. Cance, E. Kurenova, and E. Beierle. 2015. Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma. Molecular Carcinogenesis, 54:9-23.
2014
Liu, J., Y. Cheng, M. He, and S. Yao. 2014. Vascular endothelial growth factor C enhances cervical cancer cell invasiveness via upregulation of galectin-3 protein. Gynecological Endocrinology 30:461-465.
Информация представлена исключительно в ознакомительных целях и ни при каких условиях не является публичной офертой |
||||||||||||||||||||
|
||||||||||||||||||||
